Denali Therapeutics Inc. Share Price & Technical Analysis
DNLI · $18.64 (-3.42%)
Healthcare / Biotechnology
$18.64
-3.42%
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 pro…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-1% return in May, 7% avg return in past 3 year May month.
15% return in 2026, -2% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 30% | 0% | -9% | -5% | -1% | – | – | – | – | – | – | – | 15% |
| 25 | 13% | -26% | -17% | 22% | -20% | 5% | -5% | 13% | -3% | 11% | 22% | -14% | 0% |
| 24 | -24% | 22% | 3% | -25% | 20% | 23% | 6% | 3% | 19% | -11% | -6% | -18% | 11% |
| 23 | 8% | -10% | -15% | 8% | 21% | -2% | -3% | -18% | -12% | -8% | -2% | 17% | -17% |
| 22 | -23% | -6% | 0% | -27% | 3% | 21% | 15% | -18% | 11% | -8% | 8% | -13% | -37% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.09B
P/E ratio
—
52W high
$23.77
52W low
$12.58
Volume
34,22,734
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Denali Therapeutics Inc. share price today?
- Denali Therapeutics Inc. (DNLI) last traded around $18.64 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does DNLI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for DNLI. Download the app for real-time alerts.
- How can I analyze Denali Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.